Generis Celebrates New Milestone: Egyptian Drug Authority Chooses EXTEDOpulse Powered by CARA
We are proud to congratulate our partner EXTEDO on the signing of a new agreement with Digital Access to Finance (DAF), under the witness of
We are proud to congratulate our partner EXTEDO on the signing of a new agreement with Digital Access to Finance (DAF), under the witness of

Immunic Therapeutics Selects CARA Life Sciences Platform to Streamline Regulatory Operations and Accelerate Submissions CARA Life Sciences Platform Adoption Continues to Grow with Biotech Organisation

Loba biotech GmbH, a wholly owned GMP manufacturing subsidiary of pharmaand GmbH (pharma&), has chosen Generis’ CARA Life Sciences Platform to launch its digital Quality

AI-powered CARA Platform and new Starter Pack Model fuel rapid expansion across regulated sectors LONDON, UK – Generis, creator of the CARA Platform and CARA

Cytonics, a biotechnology research and development company specializing in diagnostics and therapeutics for osteoarthritis, has selected Generis, the provider of the AI-enabled CARA Life Sciences

Kwizda Pharma, a division of Kwizda Holding GmbH and a leader in the Austrian healthcare market, has selected the CARA Life Sciences Platform from Generis,
© Copyright 2002-2026, Generis Enterprise Technology Limited, all rights reserved